Article
Features and efficacy of triple-targeted therapy for patients with EGFR-mutant non-small-cell lung cancer with acquired BRAF alterations who are resistant to epidermal growth factor receptor tyrosine kinase inhibitors.
ESMO open - 1 Oct 2024
Li Y, Zeng H, Qi C, Tan S, Huang Q, Pu X, Li W, Planchard D, Tian P
Abstract excerpt
BACKGROUND: The recommended first-line treatment for advanced epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) patients is EGFR-tyrosine kinase inhibitors (EGFR-TKIs). BRAF alterations have been identified as resistance mechanisms. We aimed to identify features of and subsequent treatment strategies for such patients. PATIENTS AND METHODS: We conducted a systematic literature...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.